Kevin Fox, DO
Family Medicine · North Miami, FLNPI 1477510311
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $504 and has fallen 85.6% since, to $73 in 2025.
Across 97 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$356
- AbbVie$316
- Zimmer Biomet$225
- Lilly USA, LLC$195
- Abbott$191
- AstraZeneca$140
- plus $856 from 20 others
Across 21 payments — averaging $4544.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tolmar, Inc.$95K
What the payments were for
- Food & beverage$2,279100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 5 | $356 |
| AbbVie(2 entities) | 25 | $316 |
| Zimmer Biomet | 2 | $225 |
| Lilly USA, LLC | 11 | $195 |
| Abbott | 10 | $191 |
| AstraZeneca | 7 | $140 |
| Promius Pharma LLC | 1 | $137 |
| Exact Sciences | 4 | $108 |
| Medtronic | 2 | $101 |
| Pfizer | 4 | $72 |
| Amgen(2 entities) | 4 | $70 |
| Novartis | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Phadia US Inc. | 3 | $42 |
| Shield Therapeutics Inc | 2 | $38 |
| GSK | 1 | $22 |
| Astellas Pharma US Inc | 1 | $18 |
| Fidia Pharma USA Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Alvogen Inc | 1 | $17 |
| Neurelis, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Novo Nordisk | 1 | $13 |
| Cranial Technologies, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$150
- Promiseb Complete$137
- Sernivo$137
- TRIANEX 0.05%$137
- Persona$125
How this compares
$2,279 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $44,381 |
| EliquisApixaban | 20 | $22,114 |
| TrulicityDulaglutide | 13 | $16,316 |
| MounjaroTirzepatide | 12 | $12,907 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $1,910 |
| Lacosamide | 13 | $1,212 |
| Omeprazole | 63 | $1,100 |
| Atorvastatin Calcium | 127 | $927 |
| Tadalafil | 11 | $743 |
| Levetiracetam | 23 | $656 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $625 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 43 | $605 |
| Famotidine | 19 | $539 |
| Losartan Potassium | 80 | $533 |
| Rosuvastatin Calcium | 44 | $507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $13 | $44,38136 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $195 | $29,22325 claims |
| PfizerEliquis | $72 | $22,11420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in North Miami
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.